Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period

Öz:

Kronik Lenfositik Lösemi (KLL), eriskinlerde en sık görülen lösemidir. KLL hastalarında, son zamanlarda CD38 ZAP70 ve hTERT etkinliğinin değerlendirilmesi ve prognozun yanında evreleme ve lenfosit ikileme zamanı ile iliskisinin belirlenebilmesi için çalısmalar yapılmaktadır. KLL hastalarında prognozun değerlendirilmesi için yapılan çalısmalarda tutarsız sonuçların olduğu görülmektedir. Bu çalısmada KLL hastalarında CD38 ZAP70 ve hTERT değerleri birbirleriyle ve bilinen prognostik faktörler arasında karsılastırma yapılarak değerlendirildi. Çalısmaya dâhil edilen 30 KLL hastası ilk tanıdan sonra 5 yıl boyunca takip edildi. KLL hastaları ve kontrol olguları ortalama hTERT değeri sırasıyla 1.00±1.31 ve 3.89±3.58 idi (p< 0.05). Ortalama CD38 ve ZAP70 değerleri sırasıyla 6.20±7.60 ve 5.51±5.67 olarak saptandı. CD38 ZAP70 ve hTERT aktiviteleri arasında anlamlı bir iliski saptanmadı. Bu parametrelerle, Rai evrelemesi, periferik lenfosit değerleri, yas, cinsiyet, beta-2 mikroglobulin (B2M) ve tedaviye cevap gibi bilinen prognostik faktörler arasında istatiksel olarak anlamlı bir fark saptanmadı. KLL hastalarında 5 yıllık ortalama sağ kalım süresi %96.7 olarak saptandı. Daha büyük, takip süreleri daha uzun hasta grupları ile ileri çalısmaların yapılmasının uygun olacağı düsünülmüstür.

Anahtar Kelime:

Konular: Onkoloji

Kronik Lenfositik Lösemili Hastalarda Bilinen Prognostik Belirteçlerin CD38 ZAP70 ve hTERT Ekspresyonları ile Beş Yıllık Takip Döneminde Karşılaştırılması

Öz:

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults. Recently CD38, ZAP70 and hTERT activity have been studied for the evaluation of the prognosis of CLL besides clinical staging and lymphocyte doubling time. There are inconsistent results regarding these markers for the evaluation of the prognosis in CLL patients. In this study CD38, ZAP70 and hTERT values in CLL patients were measured to make comparisons between each other and known prognostic factors. Thirty CLL patients who were included in the study were followed up for 5 years after the initial diagnosis. The mean hTERT value in CLL and control cases were 1.00±1.31 and 3.89±3.58, respectively (p< 0.05). The mean CD38 and ZAP70 were 6.20±7.60 and 5.51±5.67, respectively. No significant association was detected between CD38, ZAP70 and hTERT activity. There was no correlation between those parameters and known prognostic parameters such as Rai staging, peripheral lymphocyte levels, age, and sex of the patients, beta-2 microglobulin and reply to treatment in CLL. The overall five-year survival rate in CLL patients is 96.7%. The overall five-year survival rate in CLL patients is 96.7%. In conclusion, further studies including larger series of patients with longer follow-up periods are recommended.

Anahtar Kelime:

Konular: Onkoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Inamdar KV, Bueso-Ramos CE. Pathology of chronic lymphocytic leukemia: an update. Ann Diagn Pathol 11: 363-389, 2007.
Yee KW, OBrien SM. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 81: 1105-1129, 2006.
Redaelli A, Laskin BL, Stephens JM, et al.The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl) 13: 279-287, 2004.
Maddocks KJ, Lin TS. Update in the management of chronic lymphocytic leukemia. J Hematol Oncol 2: 29-37, 2009.
Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 46: 219-234, 1975.
Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198-206, 1981.
Hallek M. Prognostic factors in chronic lymphocytic leukemia. Ann Oncol 19 (Suppl 4): 51-53, 2008.
Gribben JG. Molecular profiling in CLL. Hematology Am Soc Hematol Educ Program 2008; 444-449.
Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785795, 1997.
Roos G, Krober A, Grabowski P, et al. Short telomeres are associ-ated with genetic complexity, high-risk genomic aberrations, and short surviva l in chronic lymphocytic leukemia. Blood 111: 22462252, 2007.
Brezinova J, Berkova A, Vcelikova S, et al. Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia. Neoplasma 57: 215-221, 2010.
Ma L, Wang J, Jiang B, et al. Telomere length and telomerase expression activity in mononuclear cells of patients with chronic lymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17: 1409-1412, 2009.
Jovanovic R, Petrusevska G, Cevrevska L, et al. Evaluation of telomerase activity in patients with chronic B lymphocytic leukemia versus age matched controls. Correlation between telomerase activity and bone marrow infiltration. Prilozi 28: 75-86, 2007.
Terrin L, Trentin L, Degan M, et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same IgVH mutation status and different outcome. Leukemia 21: 965-972, 2007.
Tchirkov A, Chaleteix C, Magnac C, et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol 15: 1476-1480, 2004.
Verstovsek S, Giles FJ, OBrien S, et al. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res 28: 707-711, 2004.
Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 27: 453- 459, 2009.
Zenz T, Mertens D, Küppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukemia. Nat Rev Cancer 10: 37-50, 2010.
Zenz T, Fröhling S, Mertens D, et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 23: 71-84, 2010.
Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP- 70 protein expression in B-cell chronic lymphocytic leukemia. Blood 108: 853-861, 2006.
Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110: 3352- 3359, 2007.
Gentile M, Mauro FR, Guarini A, Foà R. New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. Curr Opin Oncol 17: 597-604, 2005.
Thornton PD, Fernandez C, Giustolisi GM, et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J 5: 145-151, 2004.
Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98: 181-186, 2001.
Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847, 1999.
Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98: 2633-2639, 2001.
Hus I, Kawiak J, Tabarkiewicz J, et al. ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value. Folia Histochem Cytobiol 46: 147-152, 2008.
Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 22: 211-219, 2008.
Hassanein NM, Perkinson KR, Alcancia F, et al. A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia. Am J Clin Pathol 2010; 133:708-717, 2010.
Seiler T, Döhner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Semin Oncol 33: 186-194, 2006.
Terrin L, Trentin L, Degan M, et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia 21: 965-972, 2007.
Poncet D, Belleville A, tkint de Roodenbeke C, et al. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 111: 2388-2391, 2008.
Counter CM, Gupta J, Harley CB, et al. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85: 2315-2320, 1995.
Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 103: 375-382, 2004.

APA	vural f, Karaca E, SOYER N, Gunduz C, Sahin F, KOSOVA B, SAYDAM G, ÇAĞIRGAN S, TOMBULOĞLU M, ÖZKINAY F, ÇOĞULU M (2014). Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. , 179 - 184.
Chicago	vural filiz,Karaca Emin,SOYER Nur,Gunduz Cumhur,Sahin Fahri,KOSOVA Büket,SAYDAM Güray,ÇAĞIRGAN Seçkin,TOMBULOĞLU Murat,ÖZKINAY FERİŞTAH FERDA,ÇOĞULU MUHSİN ÖZGÜR Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. (2014): 179 - 184.
MLA	vural filiz,Karaca Emin,SOYER Nur,Gunduz Cumhur,Sahin Fahri,KOSOVA Büket,SAYDAM Güray,ÇAĞIRGAN Seçkin,TOMBULOĞLU Murat,ÖZKINAY FERİŞTAH FERDA,ÇOĞULU MUHSİN ÖZGÜR Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. , 2014, ss.179 - 184.
AMA	vural f,Karaca E,SOYER N,Gunduz C,Sahin F,KOSOVA B,SAYDAM G,ÇAĞIRGAN S,TOMBULOĞLU M,ÖZKINAY F,ÇOĞULU M Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. . 2014; 179 - 184.
Vancouver	vural f,Karaca E,SOYER N,Gunduz C,Sahin F,KOSOVA B,SAYDAM G,ÇAĞIRGAN S,TOMBULOĞLU M,ÖZKINAY F,ÇOĞULU M Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. . 2014; 179 - 184.
IEEE	vural f,Karaca E,SOYER N,Gunduz C,Sahin F,KOSOVA B,SAYDAM G,ÇAĞIRGAN S,TOMBULOĞLU M,ÖZKINAY F,ÇOĞULU M "Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period." , ss.179 - 184, 2014.
ISNAD	vural, filiz vd. "Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period". (2014), 179-184.

APA	vural f, Karaca E, SOYER N, Gunduz C, Sahin F, KOSOVA B, SAYDAM G, ÇAĞIRGAN S, TOMBULOĞLU M, ÖZKINAY F, ÇOĞULU M (2014). Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. Uluslararası Hematoloji-Onkoloji Dergisi, 24(3), 179 - 184.
Chicago	vural filiz,Karaca Emin,SOYER Nur,Gunduz Cumhur,Sahin Fahri,KOSOVA Büket,SAYDAM Güray,ÇAĞIRGAN Seçkin,TOMBULOĞLU Murat,ÖZKINAY FERİŞTAH FERDA,ÇOĞULU MUHSİN ÖZGÜR Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. Uluslararası Hematoloji-Onkoloji Dergisi 24, no.3 (2014): 179 - 184.
MLA	vural filiz,Karaca Emin,SOYER Nur,Gunduz Cumhur,Sahin Fahri,KOSOVA Büket,SAYDAM Güray,ÇAĞIRGAN Seçkin,TOMBULOĞLU Murat,ÖZKINAY FERİŞTAH FERDA,ÇOĞULU MUHSİN ÖZGÜR Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. Uluslararası Hematoloji-Onkoloji Dergisi, vol.24, no.3, 2014, ss.179 - 184.
AMA	vural f,Karaca E,SOYER N,Gunduz C,Sahin F,KOSOVA B,SAYDAM G,ÇAĞIRGAN S,TOMBULOĞLU M,ÖZKINAY F,ÇOĞULU M Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. Uluslararası Hematoloji-Onkoloji Dergisi. 2014; 24(3): 179 - 184.
Vancouver	vural f,Karaca E,SOYER N,Gunduz C,Sahin F,KOSOVA B,SAYDAM G,ÇAĞIRGAN S,TOMBULOĞLU M,ÖZKINAY F,ÇOĞULU M Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. Uluslararası Hematoloji-Onkoloji Dergisi. 2014; 24(3): 179 - 184.
IEEE	vural f,Karaca E,SOYER N,Gunduz C,Sahin F,KOSOVA B,SAYDAM G,ÇAĞIRGAN S,TOMBULOĞLU M,ÖZKINAY F,ÇOĞULU M "Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period." Uluslararası Hematoloji-Onkoloji Dergisi, 24, ss.179 - 184, 2014.
ISNAD	vural, filiz vd. "Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period". Uluslararası Hematoloji-Onkoloji Dergisi 24/3 (2014), 179-184.